Alessandro explains why building expert alliances as well as unique and ambitious drug discovery strategies across multiple drug modalities; from small molecules, peptides and monoclonal antibodies, is key to address unmet needs in oncology therapeutics.
Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor
Our peptide chemistry team is excited to announce a new publication in the journal “Circulation”, which highlights the outcome of a highly successful drug discovery collaboration with Merck & co.’s world-class drug discovery group (Kenilworth, New Jersey).
We are proud for having been part of this exciting and pioneering adventure in the field of macrocycles targeting PPI. This work validates the approach of using peptide libraries from mRNA display technologies for the identification of novel oral therapeutic agents, exemplified by the invention of MK-0616. This oral PCSK9 inhibitor has the potential to be a highly effective cholesterol lowering therapy for patients.
Related Posts
